PHOENIX-- Shares of Insys Therapeutics Inc. slid in after-hours trading Thursday after the pharmaceutical company said its sales and marketing practices are under investigation. The Phoenix company said it has received a subpoena from the Office of Inspector General of the Department of Health and Human Services.» Read More
A New Jersey jury found on Friday that Merck failed to provide adequate warnings about health risks tied to its withdrawn arthritis drug Vioxx in one case, but decided that it gave adequate warning in another in two suits tried simultaneously.
Drugmaker Bayer said Friday that it will cut 6,100 jobs, more than half of them in Europe, as it integrates Schering AG into its health care unit.
The fact that Cramer wants you in this sector may confuse you. Yes, we know, this group is responsible for the subprime-lending problem we’re seeing today, but this could end up helping investors.
After the trauma of a 416-point drop in the market, Cramer likes to go fishing – bottom fishing, actually. He has 25 years of experience angling through the wrecks of portfolios that belonged to less experienced fisherman and women, and today he’s going to share his secrets with you.
Federal health advisers recommended Tuesday that the government approve the first bird flu vaccine as a stopgap measure, despite evidence it wouldn't protect most people.
The American Heart Association issued new guidelines for Pfizer's Celebrex, advising doctors the painkiller should only be used as a last resort on patients who have heart disease or a risk of developing it, CNBC's Mike Huckman reported.
Merck's stock rose before the opening bell Monday after U.S. regulators asked for more data on rival Novartis' diabetes drug, which gives Merck a leg up in the race to launch a new class of diabetes drugs.
If the Dems take over the White House in 2008, the diagnostics services sector is where you’ll want to be. That’s because a Democrat in the White House will mean no more buddy-buddy relationship between the government and pharmaceutical companies.
Genentech shares traded lower after data from a clinical trial indicated that a lower dosage of the blockbuster cancer drug Avastin was as effective as the standard dose for lung cancer patients.
Could room-temperature Byetta heat up sales? Amylin Pharmaceuticals and Eli Lilly announced that the FDA says their diabetes drug Byetta (pronounced buy-ate-uh) doesn't have to be kept in the fridge anymore. Byetta is the twice-a-day stick-pen injectable drug that helps people lower their blood sugar and lose weight
Swiss pharmaceutical giant Novartis' plans to launch diabetes treatment Galvus may be dealt a blow by the Food and Drug Administration at the end of the month, market sources told CNBC Europe.
Merck said Chief Financial Officer Judy Lewent, 58, plans to retire in July after 17 years in the post.
British pharmaceutical company Shire, which makes ADHD drug Adderall XR, said Tuesday it is buying U.S. drug maker New River Pharmaceuticals for approximately $2.6 billion, or $64 per share in cash.
Elan reported a smaller fourth-quarter loss and higher sales Tuesday, citing the expansion of its multiple sclerosis-fighting drug Tysabri as a major factor.
Onyx Pharmaceuticals is up big for the second day in a row. The stock nearly doubled yesterday on astronomical volume of 56,000,000 shares and today as I write this it's up almost 8% with more than 18,000,000 shares changing hands. So, what's up besides the stock?
Sanofi-Aventis posted higher-than-expected fourth-quarter current operating profit, despite healthcare savings in Europe as well as generic rivalry, and the drugmaker predicted more growth for 2007.
Cytyc's $24-a-share offer represents a 55% premium over the $15.53 closing price of Adeza's shares Friday on the Nasdaq Stock Market.
Shares of Onyx Pharmaceuticals soared Monday after it and its partner Bayer reported positive results from the final trial of a treatment for advanced liver cancer, paving the way for approval of the drug.
Bristol-Myers shares have run up strongly in the past two weeks on talk of a Sanofi bid, closing at $28.52 on Friday to value Bristol-Myers at more than $56 billion.
GlaxoSmithKline has won FDA approval to sell the formerly prescription-only diet drug Xenical over-the-counter. The drug can help people lose, on average, about six pounds. It'll be called "Alli" (pronounced like "ally"). GSK will split the profits with Roche, which owns prescription Xenical. ... An analyst says Alli could have peak sales of $100 million to $300 million, which would be a blockbuster by OTC-drug standards.